News und Analysen
JERAYGO (aprocitentan) recommended for approval in Europe for the treatment of resistant hypertension
Ad hoc announcement pursuant to Art. 53 LR
- Idorsia receives a positive opinion from the Committee for Medicinal Products for Human Use for JERAYGO™ (aprocitentan) as the first and only endothelin
shareribs.com - Ölpreise nach Kurssprung seitwärts
shareribs.com - BP setzt auf Teslas Supercharger
ONWARD® veröffentlicht Halbjahresergebnisse 2023 und letzte Geschäftsentwicklungen
Eindhoven, Sept. 19, 2023 (GLOBE NEWSWIRE) -- DIESE PRESSEMITTEILUNG ENTHÄLT INSIDERINFORMATIONEN IM SINNE VON ARTIKEL 7 ABSATZ 1 DER EUROPÄISCHEN MARKTMISSBRAUCHSVERORDNUNG (596/2014)
Die
US Stock Prices Up, UK Shop Prices Down
- US stocks post gains for fifth month in a row.
- Relief for Treasury as UK shop prices decline.
- HSBC announces $2bn buy back.
- Diageo posts 10.7% profit growth for year, dividend rises 5%.
shareribs.com - Ölpreise wenig bewegt - OPEC-Treffen steht an
New Phase 3 data with aprocitentan for patients with resistant hypertension has been presented at the European Society of Hypertension Annual Meeting 2023
Allschwil, Switzerland – June 26, 2023
Idorsia Ltd (SIX: IDIA) today announced that further data for aprocitentan, Idorsia’s investigational dual endothelin receptor antagonist evaluating the